Cho Jun Woo, Seo Min Soo, Kang Kyung Ku, Sung Soo Eun
Department of Thoracic and Cardiovascular Surgery, School of Medicine, Catholic University of Daegu, Daegu, Republic of Korea.
Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Republic of Korea.
Regen Ther. 2019 Aug 8;11:192-198. doi: 10.1016/j.reth.2019.07.005. eCollection 2019 Dec.
Stem cell (SC) therapy exhibits promising therapeutic efficiency against cardiovascular disease. The thymus adipose tissue (TAT) is familiar to cardiac surgeons with sternotomy; however, the application of TAT in SC therapy remains unknown. We assessed the effectiveness of TAT-derived mesenchymal SCs (TAT-MSCs) in the rat myocardial infarction (MI) model.
The human TATs were obtained from the patients who underwent coronary artery bypass graft surgery. In cell studies, we performed the cumulative population doubling level assessment, fluorescence-activated cell sorting analysis, and differentiation study. In animal studies, we segregated Sprague-Dawley rats (ischemia-reperfusion model) into three (sham, vehicle, and TAT-MSC) groups based on their corresponding treatment. Trans-thoracic echocardiogram (TTE) was obtained to assess the recovery of heart function in the 1st, 4th, 8th, and 12th week after surgical manipulations. After echocardiographic study, infarcted area of the heart was measured using triphenyl tetrazolium chloride (TTC) stain.
The sham group exhibited significantly better systolic and diastolic function (SDF) than the other groups did. After one week of TAT-MSC or vehicle injection, the TAT-MSC group exhibited a significant improvement in the E/E' value (25.75 ± 1.09 vs. 24.20 ± 0.91, < 0.001) compared to the vehicle group. Although statistically insignificant, the trend of improvement in SDF was better in the TAT-MSC group than in the vehicle group. The infarcted area measured by TTC staining was 22.81 ± 6.41% and 29.95 ± 9.09% in the TAT-MSC and vehicle groups, respectively ( = 0.04).
Although TTE results exhibited insignificant variations in SDF, a trend with improvement in the SDF of the heart was observed in the TAT-MSC group compared to the vehicle group. The infarcted area of heart indicated significant reduction in the TAT-MSC group compared to the vehicle group as confirmed by histopathological study.
干细胞（SC）疗法在治疗心血管疾病方面显示出有前景的治疗效果。胸腺脂肪组织（TAT）对于行胸骨切开术的心脏外科医生来说并不陌生；然而，TAT在SC治疗中的应用仍不清楚。我们评估了TAT来源的间充质干细胞（TAT-MSCs）在大鼠心肌梗死（MI）模型中的有效性。
从接受冠状动脉搭桥手术的患者获取人TAT。在细胞研究中，我们进行了累积群体倍增水平评估、荧光激活细胞分选分析和分化研究。在动物研究中，我们将Sprague-Dawley大鼠（缺血再灌注模型）根据相应治疗分为三组（假手术组、载体组和TAT-MSC组）。在手术操作后的第1、4、8和12周进行经胸超声心动图（TTE）检查以评估心脏功能的恢复情况。超声心动图检查后，使用氯化三苯基四氮唑（TTC）染色测量心脏梗死面积。
假手术组的收缩和舒张功能（SDF）明显优于其他组。在注射TAT-MSC或载体一周后，与载体组相比，TAT-MSC组的E/E'值有显著改善（25.75±1.09对24.20±0.91，<0.001）。尽管在统计学上无显著差异，但TAT-MSC组SDF的改善趋势优于载体组。通过TTC染色测量的梗死面积在TAT-MSC组和载体组中分别为22.81±6.41%和29.95±9.09%（=0.04）。
尽管TTE结果显示SDF的变化无显著差异，但与载体组相比，TAT-MSC组观察到心脏SDF有改善趋势。组织病理学研究证实，与载体组相比，TAT-MSC组的心脏梗死面积明显减小。
